Results 201 to 210 of about 316,809 (303)

Endoscopic small bowel therapies for type 2 diabetes

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel   +4 more
wiley   +1 more source

Beyond BMI: The Impact of the New Lancet Commission Diagnostic Criteria on Prevalence of Obesity in the United States

open access: yesObesity, EarlyView.
ABSTRACT Objective This study compared population characteristics and overall US prevalence of obesity over time using the BMI criteria and the 2025 Lancet Commission criteria (i.e., the Excess Adiposity criteria). Methods We analyzed data from 58,053 adults aged ≥ 20 years in the National Health and Nutrition Examination Survey from 1999 to 2023.
Jennifer H. Hwang, Neda Laiteerapong
wiley   +1 more source

Epidemiology of Abdominal Obesity

open access: yes, 2017
Olinto, Maria Teresa Anselmo   +2 more
openaire   +3 more sources

Twenty‐Four Month Outcomes From a Real‐World Telehealth Obesity Treatment Clinic Using Obesity Medications

open access: yesObesity, EarlyView.
ABSTRACT Objective Antiobesity medications (AOMs) are indicated for long‐term use; however, evidence of their real‐world long‐term efficacy is limited. This study describes clinical outcomes from 18‐ and 24‐month use of AOMs in a telemedicine weight management clinic.
Kathleen R. Ruddiman   +7 more
wiley   +1 more source

Anterior to posterior preoperative risk assessment of abdominal thickness compared to BMI in ventral hernias. [PDF]

open access: yesHernia
Brosnihan PJ   +6 more
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

open access: yesObesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone   +3 more
wiley   +1 more source

Prevalence of non‐alcoholic fatty liver disease and its association with different combinations of weight status and metabolic abnormalities in children aged 6–18 years

open access: yesPediatric Investigation, EarlyView.
Children with non‐overweight combined with metabolic risk factors might increase the risk of non‐alcoholic fatty liver disease (NAFLD). These findings suggest that overweight and obesity should not be the sole criterion for NAFLD screening in children. In particular, more attention should be given to non‐overweight combined with metabolic abnormalities
Peiyu Ye   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy